Cumberland Partners’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
Other funds holding AZN
Cumberland Partners's AZN Position: Q3 2026 in Review
Cumberland Partners reduced its AstraZeneca (AZN) stake by 0.88% in Q3 2026, selling an estimated $179K and leaving 120,760 shares worth $19.5M. The position accounts for 1.28% of the portfolio, ranked #26.
Cumberland Partners first reported a position in AZN in Q2 2022 and has held it in 18 quarters since. The position peaked at $28.7M in Q1 2026. 1,441 funds tracked by Wall St. Rank hold AZN as of Q3 2026.
- Cumberland Partners held 120,760 shares of AstraZeneca worth $19.5M as of Q3 2026.
- Cumberland Partners sold 1,074 AstraZeneca shares in Q3 2026, an estimated $179K.
- AstraZeneca made up 1.28% of Cumberland Partners's portfolio in Q3 2026, its #26 holding.
- Cumberland Partners first reported a position in AstraZeneca in Q2 2022 and has held it in 18 quarters since.
- Cumberland Partners's AstraZeneca position peaked at $28.7M in Q1 2026.
- 1,441 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2026.
Based on Cumberland Partners's 13F filing for Q3 2026, filed 16 Nov 2026.